期刊
CLINICAL NUCLEAR MEDICINE
卷 40, 期 11, 页码 e518-e519出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000000887
关键词
ipilimimab; monocloncal antibody; malignant melanoma; FDG-PET; CT; adverse effect; adrenalitis; neuroendocrine system
Ipilimumab is a monoclonal antibody against the inhibitory CTLA-4 receptor expressed on T cells. It provokes an upregulation of the immune system. This substance was approved by the US Food and Drug Administration in 2011 and is since increasingly used as a targeted therapeutic approach for metastasized melanoma. Ipilimumab is known to cause neuroendocrine disorders, such as hypophysitis and adrenal insufficiency. Our case of a 79-year-old patient represents an important imaging pitfall. Imaging findings of newly symmetrically and smoothly enlarged, hypermetabolic adrenal glands in the setting of previous ipilimumab therapy represent drug-induced adrenalitis and not metastatic disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据